SIMPLEX QUANTUM builds deep‑learning technology that analyzes hundreds of thousands of electrocardiograms (ECGs) to determine heart failure stage and to authenticate individual ECG waveform data. The company has received two US patents covering its heart‑failure detection and ECG authentication technologies. It is conducting a clinical trial to support a submission to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) and has initiated a pre‑submission engagement with the US Food and Drug Administration (FDA). SIMPLEX QUANTUM collaborates with partners including the University of Tokyo Hospital and Japan’s Agency for Medical Research and Development. The firm was founded in 2014 and is headquartered in Tokyo. Management positions the technology as a tool to reduce clinician workload and lower costs of care while enabling global expansion.

Total raised

$4M

Funding rounds

1

Latest round

Series A

Latest activity

Dec 2022